Despite developing standard treatments, breast cancer remains a global challenge due to its high recurrence rates and treatment-resistant tumors, emphasizing a need for more targeted treatment strategies. Standard treatments such as chemotherapy, radiation therapy, and surgery are nonspecific and significantly reduce patient quality of life. This review presents recent clinical trial findings on both single-line and combination targeted therapies, focusing on their efficacy, safety, and how biomarkers help optimize patient outcomes. The four main results of this paper indicate: PARP and PD-L1 inhibitors significantly benefit certain subgroups, an antibody drug-conjugate (ADC) is effective regardless of Trop-2 expression, adoptive cell transfer (ACT) shows promise for extremely personalized treatment, and dietary restrictions further induce anti-tumor activity. While challenges such as increased toxicity and little improvement in overall survival (OS) were observed, targeted therapies are a significant step towards creating effective, personalized treatments for breast cancer.
Andrew C. Hsieh (Wed,) studied this question.